Search
Cogent Biosciences Inc
COGTAdd to Watchlist
34.180USD
-1.100-3.12%
Close 09-09 16:00（ET）
5.86BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-09-08The current earnings forecast score of Cogent Biosciences Inc is 8.83, ranking 52 out of 377 in the Biotechnology & Medical Research industry. The average price target is 49.00, with a high of 65.00 and a low of 34.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
52.900
Target Price
+52.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cogent Biosciences Inc
COGT
12
Beigene Ltd
ONC
27
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
24
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cogent Biosciences Inc's price target?
Analysts forecast that Cogent Biosciences Inc's price target is USD 49.00, with the highest forecast at USD 65.00 and the lowest forecast at USD 34.00.
How have Cogent Biosciences IncCOGT's recent earnings per share performed?
The market expectation was USD -0.52, while Cogent Biosciences IncCOGT's earnings per share (EPS) for the previous quarter was USD -0.53. EPS for the next quarter is expected at USD -0.58.
What is the analyst rating for Cogent Biosciences Inc?
Based on the ratings of Cogent Biosciences Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.